UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39565 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 85-1908962 (State or other jurisdiction of incorporation or organization) 2165 Spr ...

Financial Data and Key Metrics Changes - In Q4 2022, the company reported net sales of $98.1 million, marking a 26% year-over-year increase and achieving mid-double-digit growth for the eighth consecutive quarter [7][101] - For the full year, net sales reached $365.9 million, up 41% year-over-year, reflecting strong consumer and provider demand despite macroeconomic challenges [7][102] - Adjusted EBITDA for the full year was $47.7 million, a 46% increase year-over-year, demonstrating profitability resilience [8][108] Business Line Data and Key Metrics Changes - Delivery systems revenue for Q4 was $50.7 million, representing a 19% year-over-year growth, while consumables revenue was $47.4 million, growing 35% year-over-year [106] - The company delivered a record 8,492 Hydrafacial systems globally in 2022, including 1,793 trade-up units to Syndeo, a 37% increase from 2021 [21] - The average selling price (ASP) of delivery systems for Q4 was $24,408, with a blended ASP for 2022 at $23,832, reflecting an 8% year-over-year increase [106] Market Data and Key Metrics Changes - The Americas region grew 44% year-over-year, APAC increased by 24%, and EMEA was up 46% for the full year, showcasing strong growth across all operating regions [8][103] - In EMEA, Q4 net sales grew 12% year-over-year, despite a $2 million foreign exchange headwind [104] Company Strategy and Development Direction - The company aims to achieve net sales of $600 million to $700 million and an adjusted EBITDA margin of 25% to 30% by 2025, focusing on profitable growth [17][18] - The launch of Syndeo internationally is planned for Q2 2023, with expectations to leverage learnings from the successful U.S. launch [19][80] - The acquisition of SkinStylus, an FDA-cleared microneedling device, is expected to enhance the product portfolio and create a new revenue stream [113][115] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential, particularly in China as COVID restrictions ease, and anticipates a strong recovery in consumer activity [20][58] - The company remains cautious yet optimistic about the operating environment, particularly in the U.S. medical spa channel, which is experiencing significant growth [41][63] - Management highlighted the importance of maintaining flexibility in marketing spend to protect margins amid potential downturns [44][46] Other Important Information - The company has invested significantly in infrastructure and capabilities over the past two years, setting the stage for future growth [97][131] - Gross margins for Q4 were reported at 66.4%, with expectations for expansion in 2023 as the company moves past its investment phase [124][132] Q&A Session Summary Question: Can you discuss the fourth quarter system ASP? - Management noted that the ASP was down sequentially due to trade-up promotions and the impact of refurbished system sales [35][83] Question: Have you seen a change in competitive pressure in the U.S.? - Management indicated that they have not observed a slowdown and are well-positioned to capture shifts in consumer interest towards scientifically endorsed products [38][41] Question: What are the expectations for revenue contribution from the SkinStylus acquisition? - Management expressed excitement about the acquisition, highlighting its complementarity to Hydrafacial and potential for future revenue growth [135][137] Question: What is the outlook for operating cash flow in 2023? - Management expects to be in a cash flow positive position, factoring in interest and capital expenditures [68][70] Question: How will the company manage marketing spend in a downturn? - Management emphasized the ability to flex marketing expenditures while maintaining a focus on protecting margins [44][46]

41% 72% 56% Net sales by segment ($mm) Q2 22 ■ Delivery Systems ■Consumables 2020 1. Trade-Up revenue only disaggregated in Q2 22. Q4 & FY 2022 financial highlights (cont'd) | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|----------------------|--------|---------------------|--------|-------|-----------------|--------------------|--------------|----------------------|--------------------------|---------|--------|--------| | | ■ Americas \n■ EMEA | | ■APA ...

Table of Contents FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-39565 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 85-1908962 (State or other jurisdiction of incorporation or organization ...

The Beauty Health Company (NASDAQ:SKIN) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Eduardo Rodriguez - Senior Director of M&A and IR Andrew Stanleick - President and CEO Liyuan Woo - CFO Conference Call Participants Oliver Chen - Cowen Korinne Wolfmeyer - Piper Sandler Jon Block - Stifel Margaret Kaczor - William Blair Allen Gong - JPMorgan Ashley Helgans - Jefferies Kyle Rose - Canaccord Genuity Bruce Jackson - The Benchmark Company Devin Weinstein - Raymond James Lin ...

← BEAUTYHEALTH® Q3 2022 Earnings Presentation November 2022 2 This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), the calculation of certain key financial and operating metrics, capital expenditures, the introduction of new products, expansion into new markets and the ability to execute certain strategic initiatives. Some of the fo ...

The Beauty Health Company (NASDAQ:SKIN) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Eduardo Rodriguez - Senior Director of M&A and Investor Relations Andrew Stanleick - President & Chief Executive Officer Liyuan Woo - Chief Financial Officer Conference Call Participants Maggie Boeye - William Blair Steph Wissink - Jefferies Oliver Chen - Cowen and Company Olivia Tong - Raymond James Korinne Wolfmeyer - Piper Sandler Jon Block - Stifel Allen Gong - JPMorgan Bruce Jackson - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-39565 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 85-19 ...

യ BEAUTYHEALTH® FIRST QUARTER 2022 EARNINGS PRESENTATION May 10, 2022 SKIN Nasdaq Listed DISCLAIMER This Presentation contains certain fooverateoking stotenents noy velde lo, but are not limited be, expectotions of hulle creating cesults of financial performance of The B the cabulation of cantain lay financial and operating metris, capital experimism into rew qocacts, exquarison into rew rocacts, expansion into rew mornes and the dobling be statements can be visentified by the use of forwardle sisch as "san ...

Financial Data and Key Metrics Changes - The company reported net sales of USD 75.4 million for Q1 2022, representing a nearly 59% year-over-year growth, driven by strong global demand for both delivery systems and consumables [27][28] - Adjusted EBITDA for the quarter was USD 2.2 million, impacted by costs associated with the SYNDEO launch, with a GAAP gross margin of 68.9% and an adjusted gross margin of 72.7%, reflecting a 50 basis point year-over-year improvement [31][32] - The full-year net sales outlook was raised to a range of USD 330 million to USD 340 million, up from the previous guidance of USD 320 million to USD 330 million [10][43] Business Line Data and Key Metrics Changes - Delivery system sales grew approximately 62% year-over-year, with a record 1,849 systems sold in Q1, including 258 trade-ups [27][32] - Consumables revenue increased by 54% year-over-year, indicating strong utilization trends, particularly in the medical channel [28][31] - The average selling price (ASP) of a delivery system was USD 21,462, influenced by trade-up activity during the SYNDEO launch [32][36] Market Data and Key Metrics Changes - In the Americas, Q1 sales increased approximately 43% year-over-year to USD 44.6 million, driven by SYNDEO and strong sales productivity [28] - In the EMEA region, net sales surged approximately 140% year-over-year to USD 17.9 million, supported by marketing activations and tradeshows [29] - APAC sales increased nearly 47% year-over-year to USD 12.9 million, despite strict lockdowns in parts of China [28][29] Company Strategy and Development Direction - The company is focused on five key strategic growth pillars, including the launch of SYNDEO, which aims to drive innovation and connected experiences [11][12] - The SYNDEO launch plan consists of three phases, with the first phase already exceeding expectations in terms of trade-up demand [10][14] - The company continues to invest in its provider network and brand awareness, including a partnership with Jennifer Lopez to enhance consumer engagement [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the current macroeconomic climate, citing strong early feedback from the SYNDEO launch and ongoing demand for products [11][22] - The company anticipates a rapid acceleration in business as cities in China reopen, similar to trends observed in other markets [22][44] - Management acknowledged challenges from global supply chain disruptions and inflation but plans to offset these through pricing initiatives and value engineering [31][37] Other Important Information - The company ended the quarter with USD 859.2 million in cash and cash equivalents, positioning it well for growth initiatives and strategic acquisitions [41] - The company has a disciplined approach to M&A, focusing on opportunities that are differentiated, complementary, and financially accretive [21] Q&A Session Summary Question: Marketing strategy and techniques - Management discussed a balanced marketing approach, combining on-ground activations with digital marketing and influencer partnerships, including the collaboration with JLo to amplify brand awareness [47][49] Question: Revenue recognition on trade-ups - Management explained that revenue from trade-ups is recognized upon shipping the new unit after taking back the old system, with cash typically collected upfront [50] Question: Trade-up mix evolution and gross margin - Management indicated that the trade-up demand is expected to slow down after the initial promotion, with a gradual rollout of SYNDEO systems impacting future margins [53][55] Question: Confidence in guidance despite uncertainties - Management attributed confidence in raised guidance to strong existing system sales and consumer demand, even before the SYNDEO launch [61][63] Question: JLo partnership details - Management highlighted JLo's significant social media following and her active involvement in promoting the new booster serum, aimed at driving consumer engagement [69][72] Question: Supply chain challenges - Management confirmed that pre-purchasing components helped meet demand, and they are working on value engineering to mitigate inflationary pressures [74][76] Question: Customer profile for trade-ups - Management noted that trade-ups are occurring across various customer profiles, including chains opting to upgrade entire fleets for consistency [80][81] Question: Glow & Go product update - Management stated that Glow & Go is still in the testing phase, with no revenue included in current guidance, and further updates will be provided in the next quarter [82]